Management option for Guillain-Barré syndrome includes which therapy?

• A. Supportive care only
• B. IVIG or plasmapheresis
• C. Antibiotics
• D. Anticoagulation

Answer: (B)

Guillain-Barré syndrome is managed with therapies that directly modulate the immune attack on the nerves, in addition to careful supportive care. The main disease-modifying options are intravenous immunoglobulin and plasmapheresis. Both work to reduce the autoimmune assault: IVIG provides normal antibodies that can blunt harmful immune responses and interfere with damaging antibodies, while plasmapheresis physically removes circulating autoantibodies and inflammatory mediators from the bloodstream. When started early, these treatments speed up recovery and can lessen the duration of severe weakness and respiratory support needs. Antibiotics don’t treat the neuropathy itself, and anticoagulation is used for preventing clots in immobilized patients but isn’t a therapy for the neuropathy. So, the therapy that fits best here is IVIG or plasmapheresis.